{"abstract":"This is notice, in accordance with 35 U.S.C. 209 and 37 CFR Part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to Peptron, Inc., a company having a place of business in Daejeon, South Korea, to practice the inventions embodied in U.S. Provisional Patent Application No. 60/309,076, filed July 31, 2001, entitled \"Long-Acting Insulinotropic Peptides and Uses Thereof\" (HHS Ref. No. E-049-2001/0-US-01); U.S. Patent No. 7,576,050, issued August 18, 2009, entitled \"GLP-1 Exendin-4 Peptide Analogs and Uses Thereof\" (HHS Ref. No. E-049-2001/0-US-03); U.S. Patent No. 8,278,272, issued October 2, 2012, entitled \"GLP-1, Exendin-4, Peptide Analogs and Uses Thereof\" (HHS Ref. No. E-049-2001/0-US-14); U.S. Patent Application No. 13/594,313, filed August 24, 2012, entitled \"GLP-1, Exendin-4, Peptide Analogs and Uses Thereof\" (HHS Ref. No. E-049-2001/0-US-21); PCT Patent Application No. PCT/US2002/024141, filed July 30, 2002, entitled \"GLP-1, Exendin-4, Peptide Analogs and Uses Thereof\" (HHS Ref. No. E-049-2001/0-PCT-02); Australian Patent No. 2002317599, issued July 17, 2008, entitled \"GLP-1, Exendin-4, Peptide Analogs and Uses Thereof\" (HHS Ref. No. E-049-2001/0-AU-04); Australian Patent No. 2008202893, issued April 26, 2012, entitled \"GLP-1, Exendin-4, Peptide Analogs and Uses Thereof\" (HHS Ref. No. E-049-2001/0-AU-10); Australian Patent Application No. 2012202081, filed April 11, 2012, entitled \"GLP-1, Exendin-4, Peptide Analogs and Uses Thereof\" (HHS Ref. No. E-049-2001/0-AU-20); Canadian Patent Application No. 2455963, filed January 29, 2004, entitled \"GLP-1, Exendin-4, Peptide Analogs and Uses Thereof\" (HHS Ref. No. E-049-2001/0-CA-05); European Patent No. 1411968, issued September 17, 2008, entitled \"GLP-1, Exendin-4, Peptide Analogs and Uses Thereof\" (HHS Ref. No. E-049-2001/0-EP-06) and validated in Germany (HHS Ref. No. E-049-2001/0-DE-11), France (HHS Ref. No. E-049-2001/0-FR-12), and Great Britain (HHS Ref. No. E-049- 2001/0-GB-13); European Patent No. 2022505, issued December 14, 2011, entitled \"GLP-1, Exendin-4, Peptide Analogs and Uses Thereof\" (HHS Ref. No. E-049-2001/0-EP-09) and validated in Germany (HHS Ref. No. E- 049-2001/0-DE-17), France (HHS Ref. No. E-049-2001/0-FR-18), and Great Britain (HHS Ref. No. E-049-2001/0-GB-19); European Patent Application No. 10177860.3, filed September 21, 2010, entitled \"GLP-1, Exendin-4, Peptide Analogs and Uses Thereof\" (HHS Ref. No. E-049-2001/0-EP-16); Indian Patent Application No. 0488/DELNP/2004, filed February 27, 2004, entitled \"GLP-1, Exendin-4, Peptide Analogs and Uses Thereof\" (HHS Ref. No. E-049-2001/0-IN-07); Japanese Patent Application No. 2003- 517083, filed February 2, 2004, entitled \"GLP-1, Exendin-4, Peptide Analogs and Uses Thereof\" (HHS Ref. No. E-049-2001/0-JP-08); Japanese Patent Application No. 2009-262568, filed November 18, 2009, entitled \"GLP-1, Exendin-4, Peptide Analogs and Uses Thereof\" (HHS Ref. No. E- 049-2001/0-JP-15; and Japanese Patent Application No. 2013-007743, filed January 18, 2013, entitled \"GLP-1, Exendin-4, Peptide Analogs and Uses Thereof\" (HHS Ref. No. E-049-2001/0-JP-22). The patent rights in these inventions have been assigned to the Government of the United States of America. The territory of the prospective Exclusive Patent License may be worldwide, and the field of use may be limited to \"Methods of using exenatide for the treatment of neurodegenerative disease in humans.\"","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2013/08/28/2013-20945.html","cfr_references":[],"citation":"78 FR 53153","comment_url":null,"comments_close_on":"2013-09-27","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before September 27, 2013 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2013-20945","effective_on":null,"end_page":53154,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2013/08/28/2013-20945.xml","html_url":"https://www.federalregister.gov/documents/2013/08/28/2013-20945/prospective-grant-of-exclusive-patent-license-use-of-exenatide-for-the-treatment-of","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2013-20945?publication_date=2013-08-28","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2013-08-28/2013-20945/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":264,"last_updated":"2026-09-21 02:15:06 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2013-08-28/pdf/2013-20945.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2013-20945.pdf?1377607845","publication_date":"2013-08-28","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2013/08/28/2013-20945.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=NIH_FRDOC_0001","supporting_documents_count":0,"docket_id":"NIH_FRDOC_0001","regulation_id_number":null,"title":"Recently Posted NIH Rules and Notices.","checked_regulationsdotgov_at":"2013-09-29T05:01:35Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":53153,"subtype":null,"title":"Prospective Grant of Exclusive Patent License: Use of Exenatide for the Treatment of Neurodegenerative Diseases","toc_doc":"Use of Exenatide for the Treatment of Neurodegenerative Diseases","toc_subject":"Exclusive Patent Licenses:","topics":[],"type":"Notice","volume":78}